Figure 1.
Kaplan–Meier curves for progression-free survival in patients treated with dabrafenib and trametinib (n=60). Median PFS and 3 year-PFS rates were 9.3 month (95% CI, 8.4–10.3) and 11.1% (95% CI, 3.3–18.9%), respectively.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.